Valion Bio, Inc. (NASDAQ:VBIO) today announced that Ukraine's Ministry of Health (MoH) has accepted the Company's regulatory dossier for Entolimod—a medical countermeasure for Acute Radiation Syndrome (ARS)—for formal review under Ukraine's Regulatory Equivalence Pathway, following the Ministry's earlier request that the Company submit the application.

Following the Ministry's request for submission, Ukraine's Ministry of Health has accepted Valion Bio's Entolimod regulatory dossier for formal review under its Regulatory Equivalence Pathway. The acceptance initiates the Ministry's scientific and regulatory evaluation and represents the first allied-nation regulatory review of Entolimod. Building on the Company's March 31, 2026 announcement of the Ministry's request, the engagement reflects an allied nation moving to secure access to a medical countermeasure for radiological preparedness.